Good morning. Shortly after he became CEO of Bayer AG in 2023, CEO Bill Anderson began waging war against bureaucracy to make ...

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...

PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), is pleased to ...

Naheed Mangi, a former Stanford coordinator, was found guilty of tampering with a breast cancer study database.

Marya Lieberman is a chemistry professor whose NIH-funded project is focused on developing a tool to detect poor-quality ...

Ginkgo Bioworks Holdings, Inc. ( NYSE: DNA) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & ...

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.